Barclays
JSPR icon

Barclays’s Jasper Therapeutics JSPR Stock Holding History

Barclays’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35.7K Buy
+2,051
New +$41.3K ﹤0.01% 4649
2026
Q1 		– Hold
0
– -$2 – 5253
2025
Q4 		– Hold
0
– – – 5179
2025
Q3 		– Hold
0
– – – 5434
2025
Q2 		– Sell
-599
Closed -$88.5K – 5163
2025
Q1 		$77.2K Sell
599
-12
-2% -$2.4K ﹤0.01% 4481
2024
Q4 		$392K Buy
611
+73
+14% +$45.6K ﹤0.01% 3972
2024
Q3 		$304K Buy
538
+410
+320% +$245K ﹤0.01% 4083
2024
Q2 		$87.1K Buy
+128
New +$92.1K ﹤0.01% 3971
2023
Q3 		– Sell
-1
Closed -$341 – 4652
2023
Q2 		$341 Buy
+1
New +$446 ﹤0.01% 4397

Other funds holding JSPR

Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
RS
R Squared Central, Hong Kong $188M AUM 18.2% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's JSPR Position: Q3 2026 in Review

Barclays opened a new position in Jasper Therapeutics (JSPR) in Q3 2026: 2,051 shares worth $35.7K. The stake represents ﹤0.01% of the portfolio and ranks #4649 among its holdings. This is a return to the name: Barclays previously reported a position in JSPR as recently as Q1 2025.

Barclays first reported a position in JSPR in Q2 2023 and has held it in 6 quarters since. The position peaked at $392K in Q4 2024. 6 funds tracked by Wall St. Rank hold JSPR as of Q3 2026.

  • Barclays held 2,051 shares of Jasper Therapeutics worth $35.7K as of Q3 2026.
  • Jasper Therapeutics was a new Barclays position in Q3 2026.
  • Jasper Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4649 holding.
  • Barclays first reported a position in Jasper Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • Barclays's Jasper Therapeutics position peaked at $392K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.